Search company, investor...
NeuroPace company logo


Founded Year




Total Raised


Market Cap


Stock Price


About NeuroPace

NeuroPace (NASDAQ: NPCE) designs, develops, manufactures, and markets implantable devices for the treatment of neurological disorders by responsive brain stimulation. It focuses on the treatment of epilepsy by reducing or eliminating the occurrence of debilitating seizures. The company was founded in 1997 and is based in Mountain View, California.

Headquarters Location

455 N Bernardo Avenue

Mountain View, California, 94043,

United States


Missing: NeuroPace's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: NeuroPace's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Research containing NeuroPace

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned NeuroPace in 1 CB Insights research brief, most recently on Mar 12, 2020.

Expert Collections containing NeuroPace

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

NeuroPace is included in 4 Expert Collections, including Game Changers 2018.


Game Changers 2018

70 items


Medical Devices

12,840 items

Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.


Digital Health

13,119 items

Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)


Health IT

7,901 items

NeuroPace Patents

NeuroPace has filed 172 patents.

The 3 most popular patent topics include:

  • Implants (medicine)
  • Neurophysiology
  • Neurological disorders
patents chart

Application Date

Grant Date


Related Topics




Surgical removal procedures, Orthopedic surgical procedures, Skeletal system, Digestive system surgery, Surgery


Application Date


Grant Date



Related Topics

Surgical removal procedures, Orthopedic surgical procedures, Skeletal system, Digestive system surgery, Surgery



Latest NeuroPace News

NeuroPace Announces Preliminary Unaudited Fourth Quarter and Full-Year 2022 Revenue and Appoints Dr. Uri Geiger to Board of Directors

Jan 9, 2023

( MOUNTAIN VIEW, Calif., Jan. 09, 2023 -- NeuroPace, Inc. , a commercial-stage medical device company focused on transforming the lives of people living with epilepsy, today announced preliminary, unaudited revenue results for the fourth quarter and full-year ended December 31, 2022 and the appointment of Dr. Uri Geiger to its Board of Directors....

NeuroPace Frequently Asked Questions (FAQ)

  • When was NeuroPace founded?

    NeuroPace was founded in 1997.

  • Where is NeuroPace's headquarters?

    NeuroPace's headquarters is located at 455 N Bernardo Avenue, Mountain View.

  • What is NeuroPace's latest funding round?

    NeuroPace's latest funding round is PIPE.

  • How much did NeuroPace raise?

    NeuroPace raised a total of $278.05M.

  • Who are the investors of NeuroPace?

    Investors of NeuroPace include Accelmed, KCK, OrbiMed Advisors, Revelation Partners, Soleus Capital Management and 14 more.

  • Who are NeuroPace's competitors?

    Competitors of NeuroPace include SetPoint Medical, INBRAIN Neuroelectronics, Neuros Medical, Theranica, Orchestra BioMed, Stimdia Medical, Lungpacer Medical, Saluda Medical, Cardionomic, Rune Labs and 47 more.

Compare NeuroPace to Competitors

Synapse Biomedical Logo
Synapse Biomedical

Synapse Biomedical (SBI) was founded to commercialize the NeuRx Diaphragm Pacing System (DPS) that has been developed over a twenty-year period at Case Western Reserve University and the University Hospitals of Cleveland. The innovative research performed at these institutions has led to significant advances in the state of the art of electrical stimulation for the treatment of chronic respiratory insufficiency.

Cala Health

Cala Health develops wearable neuromodulation therapies to deliver individualized peripheral nerve stimulation. It was founded in 2014 and is based in San Mateo, California.

Stimdia Medical

Stimdia Medical develops a non-invasive lung pacing device that reduces the time required to get a patient off a ventilator, resulting in significant cost savings. Stimdia Medical was formerly known as Andarta Medical. The company was founded in 2015 and is based in Minneapolis, Minnesota.

Theranica Logo

Theranica is a medical device company that develops advanced neuromodulation devices for migraine and other idiopathic pain conditions. It provides an FDA-cleared, prescribed, smartphone-controlled, drug-free wearable device for the treatment of episodic and chronic migraine in people aged 12 and older. The firm serves clients operating in the healthcare sector. It was founded in 2016 and is based in Netanya, Israel.

eNeura Therapeutics

eNeura Therapeutics develops the use of portable, non-invasive Transcranial Magnetic Stimulation (TMS) devices for the treatment of migraines.

Noctrix Health

Noctrix Health is developing therapeutic wearables that empower patients to take control of their chronic medical conditions.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.